Genetic Test Evaluation

understanding how genetic tests impact patient management

Cxbladder Monitor (Pacific Edge LDT)

March 1, 2018

At present, the estimated 5-year survival rate for bladder cancer is 77.3%. The high survival rate can be attributed to early detection and the high incidence of non–muscle-invasive papillary tumors that have more favorable outcomes than invasive tumors. Although the overall survival rate is high, disease recurrence is common, with invasive and costly surveillance protocols required for monitoring potential relapse. The development of adjunct noninvasive urine-based biomarker tests to assess disease recurrence offers a less invasive approach to bladder cancer recurrence surveillance.